SAMD12 Inhibitors
Chemical inhibitors of SAMD12 include a range of compounds that target various kinases and signaling pathways which are crucial for the functional regulation of this protein. Alisertib and MLN8237, both inhibitors of Aurora kinase A, play a pivotal role in the inhibition of SAMD12 by targeting phosphorylation events critical to its function. Aurora kinase A is integral to cell cycle progression and its inhibition can lead to reduced phosphorylation of proteins, including SAMD12, resulting in the disruption of its activity. Similarly, Palbociclib (PD 0332991), a CDK4/6 inhibitor, obstructs the cell cycle regulation process in which SAMD12 is implicated. By arresting the cell cycle, Palbociclib directly inhibits the function of SAMD12 as it is associated with cell cycle-related mechanisms.
Further inhibition of SAMD12 is achieved through the action of Dasatinib, Imatinib, and Bosutinib, which are tyrosine kinase inhibitors that target BCR-ABL and SRC/ABL kinases. These kinases, when inhibited, alter the signal transduction pathways critical for the phosphorylation and subsequent activation of proteins such as SAMD12, leading to its functional inhibition. Sunitinib, as a receptor tyrosine kinase inhibitor, disrupts various signaling pathways that rely on tyrosine kinase activities essential for cell proliferation and survival, which in turn inhibits the functional activity of SAMD12. The role of SAMD12 in cell division and differentiation is further inhibited by Sorafenib, which targets RAF kinase within the MAPK/ERK signaling pathway, and by Gefitinib and Erlotinib, both EGFR inhibitors that block signaling pathways implicated in the regulation of cellular proliferation. Lastly, Crizotinib, an ALK and ROS1 inhibitor, impedes the signaling pathways mediated by these kinases, which are vital to the cellular processes that SAMD12 is part of, thus potentially leading to its inhibition.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
MLN8237 | 1028486-01-2 | sc-394162 | 5 mg | $220.00 | ||
Alisertib is an Aurora kinase A inhibitor. SAMD12's function is influenced by phosphorylation events, and Aurora kinase A is implicated in such phosphorylation processes. Inhibition of this kinase by Alisertib can lead to reduced phosphorylation of proteins like SAMD12, thereby inhibiting its function. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $315.00 | ||
Palbociclib is a CDK4/6 inhibitor. CDKs are key regulators of cell cycle progression. SAMD12 has been associated with cell cycle regulation, and the inhibition of CDK4/6 can lead to a halt in the cell cycle, which can inhibit the function of cell cycle-related proteins like SAMD12. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a BCR-ABL kinase inhibitor. While primarily associated with leukemias, BCR-ABL also has broad kinase activity. Inhibition of such kinases by Dasatinib can disrupt signaling pathways that involve phosphorylation, possibly inhibiting the function of SAMD12. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin is an mTOR inhibitor. The mTOR pathway is involved in various cellular processes, including those related to protein synthesis and cell proliferation. Inhibition of mTOR by Rapamycin can lead to decreased protein synthesis, potentially inhibiting the function of SAMD12. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $25.00 $117.00 $209.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets BCR-ABL and other kinases. Inhibition of these kinases can alter signal transduction pathways that are necessary for the phosphorylation and activation of proteins like SAMD12, resulting in its functional inhibition. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $150.00 $920.00 | 5 | |
Sunitinib is a receptor tyrosine kinase inhibitor. It inhibits various signaling pathways that rely on tyrosine kinase activity for cell proliferation and survival. Inhibition of these pathways by Sunitinib can lead to functional inhibition of proteins involved in these pathways, such as SAMD12. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $56.00 $260.00 $416.00 | 129 | |
Sorafenib is a RAF kinase inhibitor. RAF kinases are part of the MAPK/ERK signaling pathway, which is involved in cell division and differentiation. Inhibition of RAF by Sorafenib could inhibit downstream signaling that regulates the activity of proteins like SAMD12. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $62.00 $112.00 $214.00 $342.00 | 74 | |
Gefitinib is an EGFR tyrosine kinase inhibitor. EGFR signaling is implicated in cell proliferation and survival. By inhibiting EGFR, Gefitinib can inhibit downstream signaling pathways that may involve functional regulation of proteins such as SAMD12. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $85.00 $132.00 $287.00 $495.00 $3752.00 | 42 | |
Erlotinib is an EGFR inhibitor, and by blocking EGFR signaling, it can inhibit cellular pathways that are involved in cell proliferation, which could lead to the functional inhibition of proteins involved in these pathways, including SAMD12. | ||||||